Merck & Co. hopes a new positive trial readout ... 10% of invasive squamous cell carcinoma within the resected tumor samples—as dual primary endpoints. But the plan was amended to make EFS ...

The partners are also studying their personalized vaccine with Keytruda as an adjuvant NSCLC treatment for those who haven't gotten neoadjuvant therapy.